Sorafenib is an oral multi-kinase inhibitor approved for patients with advanced renal cell carcinoma and hepatocellular carcinoma34 with potent activity against several receptor tyrosine kinases involved in tumour progression and tumour angiogenesis.35 Ruxolitinib is instead a selective JAK inhibitor recently approved for the treatment of primary and secondary myelofibrosis.36 Cell lines were exposed to escalating concentrations of sorafenib and ruxolitinib for 48 h, and relative ICs were obtained (Table S4). Here, NTRK1 is linked to hereditary clear cell renal cell carcinoma.